Gold is 2025’s best performer. UBS sees more upside
SAN DIEGO, CA—Gerhard Prante, a director at Cibus, Inc. (NASDAQ:CBUS), recently sold 1,150 shares of the company’s Class A common stock. The transaction, disclosed in a recent SEC filing, took place on February 20, 2025, at a price of $2.35 per share, totaling $2,702. The sale comes as CBUS shares have declined 87% over the past year, with the stock currently trading near its 52-week low of $2.11.
Following this sale, Prante retains ownership of 11,157 shares, according to the filing. The transaction was executed automatically under a Rule 10b5-1 trading plan that Prante adopted on August 16, 2024. This type of plan allows insiders to set up a predetermined schedule for selling stocks, providing an affirmative defense against accusations of insider trading.
Cibus, Inc., based in San Diego, operates in the agriculture chemicals industry. With a market capitalization of $78 million and its next earnings report due February 28, the company faces challenges, including rapid cash burn and projected losses for the current year. For deeper insights into CBUS’s financial health and growth prospects, investors can access comprehensive analysis through InvestingPro, which offers 15+ additional expert tips and detailed financial metrics.
In other recent news, Cibus has announced a direct stock offering aimed at raising approximately $22.6 million, involving the sale of about 9 million shares at $2.50 each. This capital will support the development of Cibus’s gene-edited plant productivity traits and its advanced soybean platform. Canaccord Genuity has adjusted its outlook on Cibus, lowering the stock’s price target from $20.00 to $18.00 while maintaining a Buy rating, following the company’s funding announcement. Additionally, Jefferies has reduced its price target for Cibus to $5.00 from $8.00 but continues to rate the stock as Hold. The firm’s outlook notes Cibus’s potential for improved royalty economics, contingent on expanding acreage and regulatory developments in the European Union.
In other developments, Cibus has set a new base salary of $320,000 for executive Carlo Broos, effective immediately, as reported in a recent SEC filing. The filing did not provide specifics about the previous salary or potential incentives tied to this compensation update. Cibus’s strategic focus remains on advancing its gene editing technology, with significant progress anticipated in the years 2025 to 2026, particularly in validating its single-cell cloning platform. These recent developments underscore Cibus’s ongoing efforts to enhance its agricultural productivity through innovative technologies.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.